Analytic Investors’s Myriad Genetics MYGN Stock Holding History

Analytic Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$633K	Buy	+30,749	New	+$780K	0.01%	442
2015 Q1	–	Sell	-13,555	Closed	-$462K	–	569
2014 Q4	$462K	Sell	13,555 -37,376	-73%	-$1.33M	0.01%	430
2014 Q3	$1.96M	Buy	+50,931	New	+$1.9M	0.03%	269
2014 Q2	–	Sell	-55,099	Closed	-$1.88M	–	573
2014 Q1	$1.88M	Sell	55,099 -123,823	-69%	-$3.84M	0.03%	290
2013 Q4	$3.75M	Sell	178,922 -304,183	-63%	-$7.69M	0.06%	196
2013 Q3	$11.4M	Buy	483,105 +454,355	+1,580%	+$12.9M	0.18%	136
2013 Q2	$773K	Buy	+28,750	New	+$833K	0.01%	383

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Analytic Investors's MYGN Position: Q3 2016 in Review

Analytic Investors opened a new position in Myriad Genetics (MYGN) in Q3 2016: 30,749 shares worth $633K. The stake represents 0.01% of the portfolio and ranks #442 among its holdings. This is a return to the name: Analytic Investors previously reported a position in MYGN as recently as Q4 2014.

Analytic Investors first reported a position in MYGN in Q2 2013 and has held it in 7 quarters since. The position peaked at $11.4M in Q3 2013. 224 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Analytic Investors held 30,749 shares of Myriad Genetics worth $633K as of Q3 2016.
Myriad Genetics was a new Analytic Investors position in Q3 2016.
Myriad Genetics made up 0.01% of Analytic Investors's portfolio in Q3 2016, its #442 holding.
Analytic Investors first reported a position in Myriad Genetics in Q2 2013 and has held it in 7 quarters since.
Analytic Investors's Myriad Genetics position peaked at $11.4M in Q3 2013.
224 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.